We are a clinical-stage biopharmaceutical company leveraging our proprietary ImmunoTAC™ technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Our platform enables us to strategically pair linker-payloads that modulate key disease-modifying pathways with monoclonal antibodies directed to specific disease sites. Initially, we are creating a new class of targeted immuno-oncology agents that direct a myeloid cell activator to the tumor microenvironment in solid tumors to promote cancer cell killing.
Silverback Therapeutics Presents Interim Clinical Results from the Ongoing Phase 1/1b Study of SBT6050 Alone or In Combination with Pembrolizumab in Patients with Advanced or Metastatic HER2-Expressing Solid Tumors
Silverback Therapeutics to Present Data from its Phase 1/1b Clinical Trial of SBT6050 at the European Society for Medical Oncology (ESMO) 2021 Virtual Congress
Silverback Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
Data Provided by Refinitiv. Minimum 15 minutes delayed.
09-16-2021 6:30 AM EDT
09-13-2021 11:00 AM EDT
08-10-2021 1:10 PM EDT